336 related articles for article (PubMed ID: 23568983)
61. Membranous nephropathy and cerebellar degeneration with anti-GAD antibodies in type 2 diabetes mellitus.
Folli F; Daniele G; Werner S; Kamath S; Munera JV; Abboud H; Fanti P
Acta Diabetol; 2015 Oct; 52(5):897-903. PubMed ID: 25753172
[TBL] [Abstract][Full Text] [Related]
62. Autoimmune Cerebellar Ataxia: Etiology and Clinical Characteristics of a Case Series from China.
Liu M; Ren H; Zhu Y; Fan S; Bai L; Wang J; Cui L; Guan H
Cerebellum; 2023 Jun; 22(3):379-385. PubMed ID: 35618871
[TBL] [Abstract][Full Text] [Related]
63. Rapidly progressing cerebellar ataxia associated with anti-GAD antibodies.
Quintas S; Ruiz RL; Zapata-Wainberg G; Vivancos J
Neurologia (Engl Ed); 2018 May; 33(4):273-275. PubMed ID: 27091680
[No Abstract] [Full Text] [Related]
64. Experience with immunotherapy in 3 patients with cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.
Rouco I; Hurtado P; Castaño L; Zarranz JJ
Neurologia; 2015 May; 30(4):247-9. PubMed ID: 24075582
[No Abstract] [Full Text] [Related]
65. Acute Cerebellar Ataxia Associated with Modest Elevation of Anti-GAD Antibodies in a Young Patient.
Gomez J; Jin D
Tremor Other Hyperkinet Mov (N Y); 2018; 8():620. PubMed ID: 30647991
[TBL] [Abstract][Full Text] [Related]
66. Immunological reactivity against neuronal and non-neuronal antigens in sporadic adult-onset cerebellar ataxia.
Fancellu R; Pareyson D; Corsini E; Salsano E; Laurà M; Bernardi G; Antozzi C; Andreetta F; Colecchia M; Di Donato S; Mariotti C
Eur Neurol; 2009; 62(6):356-61. PubMed ID: 19786780
[TBL] [Abstract][Full Text] [Related]
67. [Blood-brain barrier breakdown and autoimmune cerebellar ataxia].
Shimizu F
Rinsho Shinkeigaku; 2024 Mar; 64(3):148-156. PubMed ID: 38403685
[TBL] [Abstract][Full Text] [Related]
68. Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies.
Yoshikura N; Kimura A; Fukata M; Fukata Y; Yokoi N; Harada N; Hayashi Y; Inuzuka T; Shimohata T
J Neuroimmunol; 2018 Jun; 319():63-67. PubMed ID: 29685291
[TBL] [Abstract][Full Text] [Related]
69. Cerebellar ataxia and epilepsy with anti-GAD antibodies: treatment with IVIG and plasmapheresis.
Georgieva Z; Parton M
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24419643
[TBL] [Abstract][Full Text] [Related]
70. Autoantibody-mediated disorders of the central nervous system.
Irani S; Lang B
Autoimmunity; 2008 Feb; 41(1):55-65. PubMed ID: 18176865
[TBL] [Abstract][Full Text] [Related]
71. Autoantibody screening in subacute cerebellar ataxia.
Trivedi R; Mundanthanam G; Amyes E; Lang B; Vincent A
Lancet; 2000 Aug; 356(9229):565-6. PubMed ID: 10950237
[TBL] [Abstract][Full Text] [Related]
72. Brain H-MR spectroscopy in anti-GAD antibodies cerebellar ataxia.
Grimaldi G; Manto M; Jissendi Tchofo P
J Neuroradiol; 2010 Dec; 37(5):303-5. PubMed ID: 20378175
[No Abstract] [Full Text] [Related]
73. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition.
Daw K; Ujihara N; Atkinson M; Powers AC
J Immunol; 1996 Jan; 156(2):818-25. PubMed ID: 8543838
[TBL] [Abstract][Full Text] [Related]
74. Immune-mediated ataxias.
Joubert B; Rostásy K; Honnorat J
Handb Clin Neurol; 2018; 155():313-332. PubMed ID: 29891069
[TBL] [Abstract][Full Text] [Related]
75. Serum glutamate decarboxylase antibodies and neurological disorders: when to suspect their association?
Lacruz Ballester L; Fernandez-Fournier M; Puertas Muñoz I; Rodriguez Fraga O; Lastras Fernandez-Escandon C; Rodriguez de Rivera Garrido FJ; Alba Suarez EM; Tallon Barranco A
Neurol Sci; 2022 Jan; 43(1):633-641. PubMed ID: 33914193
[TBL] [Abstract][Full Text] [Related]
76. Purkinje cell cytoplasmic antibody type 1 (anti-Yo) autoimmunity in a child with Down syndrome.
Philipps G; Alisanski SB; Pranzatelli M; Clardy SL; Lennon VA; McKeon A
JAMA Neurol; 2014 Mar; 71(3):347-9. PubMed ID: 24424854
[TBL] [Abstract][Full Text] [Related]
77. Anti-GAD positive stiff-person syndrome and cerebellar ataxia: two treatable conditions that clinicians should be aware of.
Ferraz HB
Arq Neuropsiquiatr; 2012 Sep; 70(9):655-6. PubMed ID: 22990718
[No Abstract] [Full Text] [Related]
78. Efficacy of oral corticosteroids therapy in anti-glutamic acid decarboxylase antibodies cerebellar ataxia.
di Biase L; Assenza G; Iorio R; Melgari JM; Salomone G; Marano M; Muda AO; Di Lazzaro V
Parkinsonism Relat Disord; 2016 Sep; 30():78-80. PubMed ID: 27236207
[No Abstract] [Full Text] [Related]
79. Cerebellar ataxia, peripheral neuropathy, "gluten sensitivity" and anti-neuronal autoantibodies.
Lock RJ; Tengah DP; Williams AJ; Ward JJ; Bingley PJ; Wills AJ; Unsworth DJ
Clin Lab; 2006; 52(11-12):589-92. PubMed ID: 17175889
[TBL] [Abstract][Full Text] [Related]
80. [Clinical characteristics and prognosis of patients with anti-glutamic acid decarboxylase antibody-related cerebellar ataxia].
Bai L; Cai Y; Ren HT; Di WY; Liu MG; Fan SY; Guan HZ
Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(25):1935-1937. PubMed ID: 35768393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
